牛牛AI助理已提取核心訊息
Richard A. Colvin, Chief Medical Officer of bluebird bio, Inc., completed a sale of 6,770 shares of common stock on March 1, 2024. The transaction was carried out in the open market with the shares sold at a price of $1.5276 each, resulting in a total sale value of $10,341.85. Following the sale, Colvin's direct holdings in the company amount to 118,368 shares of common stock.
Richard A. Colvin, Chief Medical Officer of bluebird bio, Inc., completed a sale of 6,770 shares of common stock on March 1, 2024. The transaction was carried out in the open market with the shares sold at a price of $1.5276 each, resulting in a total sale value of $10,341.85. Following the sale, Colvin's direct holdings in the company amount to 118,368 shares of common stock.
藍鳥生物公司首席醫學官理查德·科爾文於2024年3月1日完成了6,770股普通股的出售。該交易在公開市場上進行，股票以每股1.5276美元的價格出售，總銷售價值爲10,341.85美元。出售後，科爾文在公司的直接持有量爲118,368股普通股。
藍鳥生物公司首席醫學官理查德·科爾文於2024年3月1日完成了6,770股普通股的出售。該交易在公開市場上進行，股票以每股1.5276美元的價格出售，總銷售價值爲10,341.85美元。出售後，科爾文在公司的直接持有量爲118,368股普通股。
有用
沒用